[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Philips Clinical & Medical Affairs Global\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":526},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,39,63,87,111,128,145,161,185,213,232,253,287,311,331,359,379,398,419,434,449,467,490,512],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100645323","spo2-verification-study---philips-nasal-alar-with-nellcor-oximax-spo2-board-453564624031-100645323",false,"NCT07680530","SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)","Inclusion Criteria:\n\n* Participant must have the ability to understand and provide written informed consent\n* Participant is an adult between 18-50 years of age\n* Participant must be willing and able to comply with study procedures and duration\n* Participant is a non-smoker or who has not smoked within 2 days prior to the study\n\nExclusion Criteria:\n\n* Participant is considered as being morbidly obese (defined as BMI \\>39.5)\n* Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, hands, nose, ears or forehead\u002Fskull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos (e.g. permanent, Henna) or artificial dyes (e.g. spray tan, artificial tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)\n* Females who are pregnant\n* Females who are trying to get pregnant with confirmation of positive urine pregnancy test\n* Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \\>3% as assessed with a Masimo Radical 7 (Rainbow)\n* Participants with known respiratory conditions such as: (self-reported)\n\n  * uncontrolled \u002F severe asthma\n  * flu\n  * pneumonia \u002F bronchitis\n  * shortness of breath \u002F respiratory distress\n  * unresolved respiratory or lung surgery\n  * emphysema, COPD, lung disease\n  * recent COVID with hospitalization\n* Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)\n\n  * high blood pressure: systolic \\>140 mmHg or diastolic \\>90 mmHg on 3 consecutive readings (reviewed during health screen)\n  * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)\n  * chest pain (angina)\n  * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)\n  * previous heart attack\n  * blocked artery\n  * unexplained shortness of breath\n  * congestive heart failure (CHF)\n  * history of stroke\n  * transient ischemic attack\n  * carotid artery disease\n  * myocardial ischemia\n  * myocardial infarction\n  * cardiomyopathy\n  * implantable active medical device such as pacemaker or automatic defibrillator\n* Participants with self-reported health conditions\n\n  * diabetes\n  * uncontrolled thyroid disease\n  * kidney disease \u002F chronic renal impairment,\n  * history of seizures (except childhood febrile seizures)\n  * epilepsy\n  * history of unexplained syncope\n  * recent history of frequent migraine headaches\n  * recent symptomatic head injury (within the last 2 months) with continued symptoms\n  * cancer requiring chemotherapy, radiation, or current treatment - Participants with known clotting disorders (self reported)\n  * history of bleeding disorders or personal history of prolonged bleeding from injury\n  * history of blood clots\n  * hemophilia\n  * current use of blood thinner: prescription or daily use of aspirin\n  * Sickle Cell Trait or Disease - Participants with self-reported dermatological conditions at sensor application sites\n  * severe dermatitis\n  * hyperkeratosis\n  * nail fungus - Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self reported)\n* Participants with severe allergies to iodine (only applicable if iodine is used)\n* Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)\n* Participants with allergies to ultrasound gel\n* Failure of the Perfusion Index Ulnar\u002FUlnar+Radial Ratio test (Ratio \\\u003C0.4)\n* Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits.\n* Unwillingness or inability to remove makeup, creams, lotions, sunscreen, or powders from application sites on the nose or ear.\n* Unwillingness or inability to cut\u002Ftrim fingernail(s) of test digits if determined length will interfere with correct application of the sensor\n* Piercing at application site of the ear or nose sensors that may interfere with correct placement of sensor\n* Participants received colored intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring)\n* Surgical hardware in pathway of Device Under Test\n* Other known health conditions should be considered upon disclosure",true,"ALL","18 Years","50 Years",{"count":20,"type":21},45,"ESTIMATED","OBSERVATIONAL","The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.",[25],"Pulse Oximetry","RECRUITING","2026-06-25",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":30},"2026-05-28",{"date":34,"type":21},"2026-06-24",{"name":36,"class":37},"Philips Clinical & Medical Affairs Global","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100558302","radiation-free-study-100558302","NCT06549348","Radiation Free Study","RadFree","Inclusion Criteria:\n\n* Subject will be undergoing a primary Fenestrated Endovascular Aortic Repair (FEVAR) procedure (including subjects with prior infrarenal EVAR or open repair) that includes the incorporation of visceral arteries into the repair.\n* Subject is able to give informed consent and is 18 years of age or older, or of legal age to give informed consent per state or national law.\n* Subject has a life expectancy of at least 2 years\n* Target vessels to be included are the Celiac Trunk, Superior Mesenteric Artery and Renal Arteries\n\nExclusion Criteria:\n\n* Subjects undergoing an endovascular procedure that include branches or iliac branched devices (IBD) in the repair\n* Subject treated for re-intervention \u002F staged procedure post-primary FEVAR procedure\n* Subjects intended to be treated for more than 4 target vessels (not counting the contralateral gate)\n* Subject treated for an emergent (\\\u003C24hrs after emergence) procedure\n* Subject with connective tissue disorder eg, Marfan's or Ehlers Danlos Syndrome\n* Subject with contrast allergies\n* Subject participates in a potentially confounding drug or device trial during the course of the study. Co-enrollment in concurrent trials may be allowed provided that pre-approval is obtained from Philips.\n* All vulnerable subjects such as immuno-compromised subjects, subjects lacking the capacity to provide consent, patients in emergency situations, pregnant or breast-feeding women, or any other subject who meets an exclusion criteria, according to applicable national laws, if any.\n* Subject unwilling or unable to comply with the protocol unable to understand verbal and\u002For written informed consent",{"count":47,"type":21},182,"INTERVENTIONAL",[50],"NA","This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable.\n\nPrimary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)",[53],"Aortic Aneurysm","2026-06-11",{"date":56,"type":30},"2026-06-15",{"date":58,"type":30},"2025-07-03",{"date":60,"type":21},"2027-06-30",{"name":36,"class":37},11,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":48,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100509708","the-thor-ide-study-100509708","NCT05916950","The THOR IDE Study","THOR","Inclusion Criteria:\n\n* Patient age is ≥18 years\n* Patient agrees to participate and to comply with the protocol by signing an IRB approved patient consent form\n* Patient is able to walk unassisted or with non-motorized assistive devices\n* Patient has PAD with documented Rutherford Class 2-4 of the target limb\n* Anticipated life expectancy \\>12 months, in the opinion of the investigator at the time of enrollment.\n\nAngiographic Inclusion Criteria:\n\n* Patient has de novo atherosclerotic disease of the native SFA and\u002For the popliteal arteries\n* Target lesion has ≥70% diameter stenosis by investigator via visual assessment\n* Target lesion length ≤150mm. Total treatment zone may not exceed 150mm, and may include one or more lesions.\n* Chronic total occlusion lesion length is \\\u003C100mm of the total ≤150mm target lesion\n* Minimum reference vessel diameter (RVD) 4.0mm by visual estimate\n* Target lesion crossed and intraluminal guidewire placement confirmed; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations\n* At least one patent tibial vessel (defined as \\\u003C50% stenosis) with runoff to the foot\n* Target lesion has moderate to severe calcification graded using the Peripheral Academic Research Consortium (PARC) criteria\n\nExclusion Criteria:\n\n* Patient has active infection requiring antibiotic therapy\n* Stenting planned within the target lesion\n* Known positive for COVID-19 within the last 2 weeks and actively symptomatic\n* Pregnant (positive pregnancy test) or currently breast feeding\n* Evidence of Acute Limb Ischemia in the target limb within 7 days prior to procedure\n* Cerebrovascular accident (CVA) \\\u003C60 days prior to procedure\n* Myocardial infarction \\\u003C60 days prior to procedure\n* History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to baseline screening\n* Known contraindication to aspirin, or antiplatelet\u002Fanti-coagulant therapies required for procedure\u002Ffollow-up\n* Known allergy to contrast media that cannot adequately be premedicated prior to study procedure\n* History of Thrombophilia, Heparin-induced Thrombocytopenia (HIT), or Heparin-induced Thrombotic Thrombocytopenia Syndrome (HITTS)\n* Serum creatinine ≥2.5mg\u002FdL (unless dialysis-dependent) tested within 30 days prior to procedure\n* Planned lower limb major amputation (above the ankle)\n* Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned on target limb for within 30 days following index procedure, with the exception of diagnostic angiography\n* Currently participating in any investigational device or drug clinical trial that, in the opinion of the investigator, will interfere with the conduct of the current study\n* The use of specialty balloons, re-entry or additional atherectomy devices is required for treatment of the target lesion.\n\nAngiographic Exclusion Criteria:\n\n* Subject has significant stenosis (\\>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated.\n* Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to the target site at the time of the index procedure.",{"count":71,"type":21},155,[50],"The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD).\n\nThe main question\\[s\\] it aims to answer are:\n\n* Is the Thor system safe in treating these lesions\n* Does the Thor system work to treat these lesions\n\nParticipants will:\n\n* Receive treatment with the Thor system\n* Have follow-up visits at Discharge, 30 days, 6 months, and 12 months",[75,76,77,78],"Peripheral Artery Disease","Peripheral Artery Stenosis","Peripheral Artery Calcification","PAD","2026-06-10",{"date":54,"type":30},{"date":82,"type":30},"2024-10-29",{"date":84,"type":21},"2027-12",{"name":36,"class":37},29,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":22,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":38},"100638837","spectral-precise-image-colon-cancer-100638837","NCT07620444","Spectral Precise Image-Colon Cancer","CT Image Quality Assessment of Colon Cancer Using Spectral Precise Image Deep Learning Reconstruction","Inclusion Criteria:\n\n1. Patients pathologically confirmed with colon cancer via endoscopic biopsy.\n2. Patients who underwent preoperative abdominopelvic enhanced spectral CT.\n3. Study participant with age ≥ 18 years old.\n4. Study participants that have signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. The clinical data or pathological information is considered incomplete after evaluation by the investigator.\n2. The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis.\n3. Data of patients deemed inappropriate for inclusion after evaluation by the investigator.",{"count":95,"type":21},100,"1 Day","This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.",[99],"Colon Cancer Patients",[101],"Spectral Precise Image","NOT_YET_RECRUITING","2026-05-27",{"date":105,"type":30},"2026-06-02",{"date":107,"type":21},"2026-06-01",{"date":109,"type":21},"2026-12-31",{"name":36,"class":37},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":127,"locationsCount":4},"100637236","ai-based-metal-artifact-reduction-pmar-100637236","NCT07619404","AI Based Metal Artifact Reduction-PMAR","Clinical Application of AI Based Metal Artifact Reduction and Its Comparison With Orthopedic Metal Artifact Reduction (O-MAR) and Conventional Image","Inclusion Criteria:\n\n1. Images come from patients aged ≥ 18 years,\n2. Images come from patients with screws in lumber spine after internal fixation surgery underwent follow up Incisive CT scan;\n3. Images come from patients who comply with the requirements of informed consent at the study site.\n\nExclusion Criteria:\n\n1. Patients with other metal objects inside or outside the body\n2. There is movement during the CT scan, causing by breathing etc. artifact affecting image quality\n3. Data is considered unsuitable for enrollment based on the investigator's evaluation due to incomplete clinical data or radiological information etc.","80 Years",{"count":120,"type":21},220,"The study is going to enroll about 220 consecutive patients with screws in lumber spine after internal fixation surgery who underwent follow-up assessment using Incisive CT according to the department standard of care. Retrospective data sets will be reconstructed into conventional image, the O-MAR algorithm, and Precise-MAR. Three blinded, independent radiologists evaluate both qualitative and quantitative analysis of image quality of surrounding tissue and artifact. Statistical analysis included the Friedman test, Wilcoxon signed-rank test, and Levene test.",[123],"Lmbar Spine With Screws",{"date":105,"type":30},{"date":56,"type":21},{"date":109,"type":21},{"name":36,"class":37},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":38},"100639826","spectral-precise-image-study-for-brain-tumors-100639826","NCT07620470","Spectral Precise Image Study for Brain Tumors","Clinical Study for Exploring Image Quality the Spectral Precise Image in Patients With Diagnosed Intracranial Tumors","Inclusion Criteria:\n\n1. Patients with clinical and radiology (MRI\u002FCT) diagnosed brain tumors.\n2. Patients who underwent contrast enhanced scans using the Spectral CT 7500.\n3. Study participants with age ≥ 18 years old.\n4. Study participants that have signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n1. The clinical data or radiological information is considered incomplete after evaluation by the investigator.\n2. Study participant that was enrolled in this study in the past\n3. Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation",{"count":136,"type":21},120,"The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.\n\nThe main question it aims to answer is:\n\nThe Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions",[139],"Brain Tumors",{"date":105,"type":30},{"date":142,"type":30},"2025-11-28",{"date":109,"type":21},{"name":36,"class":37},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":160,"locationsCount":38},"100639321","spectral-precise-image-study-for-coronary-artery-100639321","NCT07620457","Spectral Precise Image Study for Coronary Artery","Image Quality Evaluation of Coronary CT Angiography Using Deep Learning-Based Spectral Precise Image Reconstruction","Inclusion Criteria:\n\n1. Datasets from Patients who underwent spectral coronary CT angiography (CCTA).\n2. Datasets from study participants with age ≥ 18 years old.\n3. Scan parameters that meet the criteria defined in the 5.4.3.\n\nExclusion Criteria:\n\n1. The clinical data information is considered incomplete after evaluation by the investigator.\n2. The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis.\n3. Data of patients deemed inappropriate for inclusion after evaluation by the investigator.",{"count":153,"type":21},200,"This is a single-center, comparative, observational, retrospective data study. Datasets from patients who underwent spectral coronary CT angiography (CCTA) for suspected coronary artery disease (CAD) or other diagnosis needs as part of their routine clinical evaluation will be included.",[156],"Cardiac",{"date":105,"type":30},{"date":107,"type":21},{"date":109,"type":21},{"name":36,"class":37},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100490998","nibp-validation-study-100490998","NCT05673408","NIBP Validation Study","Non-Invasive Blood Pressure Validation Study","Inclusion Criteria:\n\n* Patient admitted into the NICU, PICU, ICU, or OR (operating room)\n* Adult aged 18 years and older, or parent\u002Flegal guardian of minor, willing and able to understand and provide informed consent\u002Fassent\n* Indication for NIBP cuff\n* Indication for radial arterial line for Subject Group 2 and Subject Group 3, and radial or umbilical arterial line for Subject Group 1\n* Meet the following stratification criteria across the study:\n\nStratification (per the ISO 81060-2:2018\u002FAmd-2:2024):\n\n* Subject Group 1:\n\n  * At least 3 patients shall be \\\u003C1000 g in weight\n  * At least 3 patients shall be 1000 to 2000 g in weight\n  * At least 3 patients shall be \\> 2000 g in weight\n  * At least 3 patients shall be ≥ 29 days and \\\u003C 1 year of age\n  * At least 3 patients shall be ≥ 1 year and \\\u003C 3 years of age\n  * The remaining patients may be from any of the above age or weight groups in order to complete the sample size\n  * A patient can be in more than one category simultaneously\n* Subject Group 2:\n\n  * At least 30% male, 30% female\n  * Limb circumference distributed as specified in ISO81060-2:2018\u002FAmd2:2024.\n* Subject Group 3:\n\n  * At least 30% male, 30% female\n  * Limb circumference distributed as specified in ISO81060- 2:2018\u002FAmd-2:2024.\n  * At least 10% SBP ≤ 100mmHg\n  * At least 10% SBP ≥ 160mmHg\n  * At least 10% DBP ≤ 70mmHg\n  * At least 10% DBP ≥ 85mmHg\n\nExclusion Criteria:\n\n* Inability to place the study device appropriately due to patient's anatomy or condition\n* Known pregnancy or lactating women (self-report)\n* Patients treated with an intra-aortic balloon pump\n* Aortic and mitral regurgitation (\\> 2 nd degree)\n* Measurements taken in the lateral position\n* Currently participating in another clinical trial with any product, treatment and\u002For medication that clinically interferes with the study endpoint(s)\n* If valid SBP reference measurements for lateral difference is \\> 15 mmHg (except for neonates with umbilical A-line)\n* If valid DBP reference measurements for lateral difference is \\> 10 mmHg (except for neonates with umbilical A-line)\n* At the Principal Investigator's discretion, subject does not qualify to participate in the study for any reasons that are not mentioned above",{"count":169,"type":21},189,"The purpose of this study is to compare measurements of blood pressure (BP) between the Philips non-invasive blood pressure (NIBP) system (including NIBP cuff and portable patient monitor) and invasive radial for Subject Group 2 and 3, and radial or umbilical arterial line for neonates (A-line) in critical care patients.",[172],"Critical Illness",[174,175],"NIBP Validation","Non-Invasive Blood Pressure","2026-05-21",{"date":178,"type":30},"2026-05-26",{"date":180,"type":30},"2023-06-23",{"date":182,"type":21},"2027-03-31",{"name":36,"class":37},5,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":193,"studyType":22,"phases":4,"briefSummary":194,"conditions":195,"keywords":202,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100635406","hummingbird-ice-study-100635406","NCT07552272","Hummingbird ICE Study","Inclusion Criteria:\n\n* 18 years of age\n* Willing to provide written, dated and signed, informed consent\n* Undergoing percutaneous cardiac intervention procedures in with VeriSight Pro is used\n\nExclusion Criteria:\n\n* Contraindicated for ICE catheter placement or considerations that make placement of VeriSight not technically feasible\n* Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease",{"count":192,"type":21},1000,"2 Days","The goals of this observational study are to collect data and ultrasound images using the Philips VeriSight Pro intracardiac echocardiography (ICE) catheter to assess safety and effectiveness and to support development efforts of the VeriSight Pro imaging platform.",[196,197,198,199,200,201],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Atrial Fibrillation (AF)","Valve Disease, Heart","Atrial Septal Defect","Patent Foramen Ovale","Tricuspid Valve Disease",[203,204],"Intracardiac Echocardiography (ICE)","VeriSight","2026-05-18",{"date":207,"type":30},"2026-05-22",{"date":209,"type":21},"2026-07",{"date":211,"type":21},"2031-07",{"name":36,"class":37},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":38},"100633057","next-gen---philips-optimus-100633057","NCT07521735","NEXT GEN - PHILIPS OPTIMUS","SPO2 NEXT GEN VALIDATION STUDY - PHILIPS OPTIMUS","Inclusion Criteria:\n\n* Participant must have the ability to understand and provide written informed consent.\n* Participant is an adult between 18-50 years of age.\n* Participant must be willing and able to comply with study procedures and duration.\n* Participant is a non-smoker or who has not smoked within 2 days prior to the study.\n* Male or female assigned at birth of any race.\n\nExclusion Criteria:\n\n* Participant is considered as being morbidly obese (defined as BMI \\>39.5)\n* Compromised circulation (i.e., Raynaud's Syndrome), injury, open wound, or physical malformation of fingers, toes, hands, ears or forehead\u002Fskull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)\n* Females who are pregnant\n* Females who are trying to get pregnant (with confirmation of positive urine pregnancy test unless the participant is known to be not of child-bearing potential)\n* Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \\>3% as assessed with a Masimo Radical 7 (Rainbow)\n* Participants with known respiratory conditions such as: (self-reported)\n\n  * uncontrolled \u002F severe asthma,\n  * flu,\n  * pneumonia \u002F bronchitis,\n  * shortness of breath \u002F respiratory distress,\n  * unresolved respiratory or lung surgery,\n  * emphysema, COPD, lung disease\n  * Recent COVID with or without hospitalization (last 2 months)\n* Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)\n\n  * high blood pressure: systolic \\>140 mmHg or diastolic \\>90 mmHg on 3 consecutive readings (reviewed during health screen)\n  * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)\n  * chest pain (angina)\n  * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)\n  * previous heart attack\n  * blocked artery\n  * unexplained shortness of breath\n  * congestive heart failure (CHF)\n  * history of stroke\n  * transient ischemic attack\n  * carotid artery disease\n  * myocardial ischemia\n  * myocardial infarction\n  * cardiomyopathy\n  * implantable active medical device such as pacemaker or automatic defibrillator\n* Self-reported health conditions as identified in the Health Assessment Form\n\n  * diabetes,\n  * uncontrolled thyroid disease,\n  * kidney disease \u002F chronic renal impairment,\n  * history of seizures (except childhood febrile seizures),\n  * epilepsy,\n  * history of unexplained syncope,\n  * recent history of frequent migraine headaches,\n  * recent symptomatic head injury (within the last 2 months),\n  * Cancer requiring chemotherapy, radiation, or current treatment.\n* Participants with known clotting disorders (self-reported)\n\n  * history of bleeding disorders or personal history of prolonged bleeding from injury\n  * history of blood clots\n  * hemophilia\n  * current use of blood thinner: prescription or daily use of aspirin\n  * Sickle Cell Trait or Disease\n* Participants with self-reported dermatological conditions at sensor application sites\n\n  * severe dermatitis\n  * hyperkeratosis\n  * nail fungus\n* Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)\n* Participants with severe allergies to iodine (only applicable if iodine is used)\n* Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)\n* Participants with allergies to ultrasound gel\n* Failure of the Perfusion Index Ulnar\u002FUlnar+Radial Ratio test (Ratio \\\u003C0.4)\n* Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits (Note: Certain bruising may still allow participants to participate if the condition is noted and would not affect the sites utilized.)\n* Unwillingness or inability to cut\u002Ftrim fingernail(s) of test digits if determined length will interfere with correct application of the sensor.\n* Participant received intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, indiocarmine, dyes used in cardiac output monitoring)\n* Surgical hardware in pathway of Device Under Test\n* Other known health conditions should be considered upon disclosure in health assessment form.\n* Participants with uneven skin tone at the sensor site or at the forehead\n* Participants who were previously enrolled and\u002For included in the terminated Optimus Validation study",{"count":221,"type":21},36,"The purpose of this clinical study is to validate the SpO2 accuracy performance of the sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry.",[25],"2026-04-07",{"date":226,"type":30},"2026-04-13",{"date":228,"type":30},"2026-03-09",{"date":230,"type":21},"2026-04-03",{"name":36,"class":37},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":48,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},"100416363","we-trust-workflow-optimization-to-reduce-time-to-endovascular-reperfusion-for-ultra-fast-stroke-treatment-100416363","NCT04701684","WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)","Inclusion Criteria:\n\n* Subject is 18 years of age or older, or of legal age to give informed consent per state or national law.\n* Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points.\n* Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2).\n* Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) \\\u003C 6 hours from symptom onset OR wake-up stroke with time last known well of \\\u003C 12 hours and symptoms discovered within 6 hours from arrival time at a stroke center. Symptom onset is defined as point in time the patient was last known well (at baseline).\n* Informed consent obtained from patient or his or her legally designated representative (if locally required).\n* Angiography suite immediately available.\n* Endovascular treatment team immediately available (Neurologist, Neurointerventionalist, Anesthesiologist, Nursing, Technicians as per local standard practice)\n\nExclusion Criteria:\n\nClinical exclusion criteria:\n\n* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 3.0\n* Known baseline platelet count \\\u003C 30.000\u002FμL\n* Baseline blood glucose of \\\u003C 50mg\u002FdL (\\\u003C 2.78mmol\u002Fl)\n* For patients receiving thrombolysis: severe, sustained hypertension (SBP \\> 185 mm Hg or DBP \\> 110 mm Hg). Note: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA\u002FASA guidelines recommended medication (including IV antihypertensive drips), the patient can be enrolled.\n* Patients from a transfer center (Primary Stroke Center) with a CT\u002FMR that is not required to be redone in the Comprehensive Stroke Center as per discretion of the physician or per local standards (e.g. CT\u002FMR less than 90 minutes old).\n* Patients in coma (NIHSS item of consciousness \\>1) defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).\n* Patients with extreme vomiting\n* Patients that are extremely agitated\n* Seizures at stroke onset which would preclude obtaining a baseline NIHSS\n* Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n* Patients acquired stroke while in-hospital\n* History of life-threatening allergy (more than rash) to contrast medium\n* Cerebral vasculitis\n* Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)\n* Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).\n* Patients with unstable clinical status who require emergent life support care\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.\n* Subject participates in a potentially confounding drug or device trial during the course of the study.\n* Woman of childbearing potential who is known to be pregnant on admission.\n* Subject meets an exclusion criteria according to national law (e.g. age, pregnant woman, breast feeding woman)\n* Subject is Philips employee or their family members residing with this Philips employee.",{"count":239,"type":21},594,[50],"The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.",[243],"Stroke, Acute","2026-03-03",{"date":246,"type":30},"2026-03-05",{"date":248,"type":30},"2021-06-23",{"date":250,"type":21},"2027-04-01",{"name":36,"class":37},23,{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":286},"100627521","respiration-from-pleth-validation-100627521","NCT07449715","Respiration From Pleth Validation","RfP Validation","Inclusion Criteria:\n\n1. Adult Participants (defined as aged 18 years or older): Willing and able to understand and provide written informed consent\n2. UK Pediatric subjects:\n\n   * Aged 16 years and older willing and able to understand and provide written informed consent\n   * Aged 4-15 years and their legal guardians willing and able to understand and provide written informed consent\u002Fassent\n3. US Pediatric Participants: aged 4 to 17 years and their parent\u002Flegal guardian are willing and able to understand and provide written informed assent\u002Fconsent\n4. Participant weight is within intended use of at least one SpO2 sensor under test as time of enrollment.\n\n   * M1191T, adult participants \\> 50 kg\n   * M1192A, pediatric participants 15-50 kg\n   * Nasal Alar Sensor, adult and pediatric participants ≥ 15 kg\n   * M1194A, adult and pediatric participants \\> 40 kg\n5. Willing and able to wear study devices for the entirety of study procedures\n6. Undergoing regular spot-check measurements as per the site's standard of care\n\nExclusion Criteria:\n\n1. Palliative patients\n2. Patients with tremors, cardiac pacemakers, or known atrial fibrillation\n3. Patients receiving oxygen supplementation at the time of study participation\n4. Critically ill patients with severe physiological instability\n5. Pregnant and\u002For lactating patients (self-reported)\n6. Injury, wounds, and\u002For physical malformation of any sensor application site (e.g., fingers, nose, ear)\n7. Self-reported severe contact allergies to standard adhesives, latex, and\u002For other materials found in pulse oximetry sensors\n8. Unwillingness or inability to remove colored nail polish or artificial nails from the application site\n9. Unwillingness or inability to remove foreign objects, such as nose and\u002For ear jewelry from sensor application sites\n10. Nail fungus on application site\n11. Severe dermatitis or hyperkeratosis (e.g. ichthyosis) at sensor application site","4 Years",{"count":262,"type":21},113,"This observational clinical investigation evaluates the performance of respiratory rate derived from the plethysmography waveform (Respiration from Pleth, RfP) using Philips FAST Pulse Oximetry technology. Adult and pediatric inpatients will undergo noninvasive monitoring using age- and weight-appropriate SpO₂ sensors and capnography, with capnography serving as the reference standard. The study assesses accuracy, mean bias, precision, and time to first valid respiratory-rate value across continuous and spot-check conditions. No device outputs are used for clinical decision-making, and all procedures occur during a single study visit.",[265],"Respiratory Rate Monitoring",[267,268,269,270,271,272,273,274,275,276,277],"Respiration rate","Capnography","Plethysmography","RfP Algorithm","Respiration from plethysmography","Device performance validation","Pulse oximetry","Vital signs monitoring","FAST Pulse Oximetry technology","SpO₂ sensors","Pleth-derived respiratory rate","2026-02-26",{"date":280,"type":30},"2026-03-04",{"date":282,"type":30},"2026-02-06",{"date":284,"type":21},"2026-05-25",{"name":36,"class":37},2,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":310},"100584917","the-high-fidelity-hydraulic-coupling-upper-arm-cuff-assessment-of-limits-safety-and-effectiveness-hipulse-trial-100584917","NCT06895590","The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial","HIPULSE","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Indication for NIBP cuff\n* Indication for a radial arterial line\n* Subject or legal authorized representative is able to understand and speak the local language (also Spanish for US sites) to provide voluntary written informed consent prior to study procedures\n\nThe following stratification criteria must be met across the study sites and hence targeted enrollment may be required:\n\n* Age of every patient 18+; at least 30% \\> 65 years, 30% ≤ 65 years\n* At least 30% male, 30% female\n* Minimum number of subjects needed to test each size cuff (per ISO81060-2:2018\u002FAMD2:2024, based on limb circumference range):\n\n  * Adult Small (19-27 cm) = 165\\*\\[8\u002F(2\\*24)\\] = 28\n  * Adult (25-34 cm) = 165\\*\\[9\u002F(2\\*24)\\] = 31\n  * Adult Large Short (30-40 cm with severely conical arm) = 165\\*\\[10\u002F(2\\*24)\\] = 35\n  * Adult Large (32-43 cm) = 165\\*\\[11\u002F(2\\*24)\\] = 38\n* At least 40% of the subjects within each cuff size shall have a limb circumference that lies within the upper half of the specified range of use of the cuff\n* At least 40% of the subjects within each cuff size shall have a limb circumference within the lower half of the specified range of use of the cuff\n* At least 10% SBP measurements ≤ 100 mmHg\n* At least 10% SBP measurements ≥ 160 mmHg\n* At least 10% DBP measurements ≤ 70 mmHg\n* At least 10% DBP measurements ≥ 85 mmHg\n\nExclusion Criteria:\n\n* Emergency surgery\n* Surgeries in which both arms are tucked\n* Inability to place the Philips AMC appropriately due to subject anatomy or condition\n* Known pregnancy or lactating women (self-report)\n* Patients treated with an intra-aortic balloon pump\n* Aortic and mitral regurgitation (\\> 2nd degree), if known\n* Measurements taken in the lateral position\n* Pressure of the arterial line system, when tested at 100 mmHg with the VeriCal device, exceeds the +\u002F- 2 mmHg threshold\n* Currently participating in an investigational drug or another device study that clinically interferes with the study endpoints\n* Upper arm circumference \\\u003C 19 cm or \\> 43 cm\n* BMI \\> 45\n* If the average of 3 baseline NIBP lateral difference measurements for SBP is \\> 15 mmHg or for DBP is \\> 10 mmHg\n* At the PI's discretion, subject does not qualify to participate in the study for any reasons that are not mentioned above",{"count":295,"type":21},205,"The purpose of this study is to compare measurements of blood pressure (BP) and fluid responsiveness between the Philips AMC and invasive radial arterial line in surgical patients.",[298,299],"Non-cardiac Surgical","Intensive Care Unit (ICU)",[301],"BP, FR, DBP, MAP, SBP, A-line","2026-02-24",{"date":304,"type":30},"2026-02-27",{"date":306,"type":30},"2025-10-02",{"date":308,"type":21},"2026-02",{"name":36,"class":37},4,{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":286},"100584918","the-high-fidelity-hydraulic-coupling-upper-arm-cuff-assessment-of-limits-safety-and-effectiveness-hipulse-trial-cardiac-output-study-100584918","NCT06895603","The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial (Cardiac Output Study)","CO","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Indication for PAC (Swan-Ganz)\n* Indication for radial arterial line\n* Subject or legal authorized representative is able to understand and speak the local language (also Spanish is also accepted for US sites) to provide voluntary written informed consent prior to study procedures\n\nExclusion Criteria:\n\n* Emergency surgery\n* ICU or surgical positioning where both arms are tucked\n* Inability to place the Philips AMC appropriately due to subject anatomy or condition\n* Known pregnancy or lactating women (self-report)\n* Patients treated with an intra-aortic balloon pump\n* Measurements taken in the lateral position\n* Currently participating in an investigational drug or another device study that clinically interferes with the study endpoints\n* Upper arm circumference \\\u003C 19 cm or \\> 43 cm\n* BMI \\> 45\n* At the PI's discretion, subject does not qualify to participate in the study for any reasons that are not mentioned above",{"count":319,"type":21},75,"The purpose of this study is to compare cardiac output (CO), fluid responsiveness, and related measurements between the Philips AMC and PAC (Swan-Ganz) in ICU or surgical patients.",[322,323,324],"ICU","Pulmonary Artery Catheter (PAC)","Swan-Ganz Catheter",{"date":304,"type":30},{"date":327,"type":30},"2025-10-28",{"date":329,"type":21},"2026-06",{"name":36,"class":37},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":48,"phases":340,"briefSummary":341,"conditions":342,"keywords":348,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100621239","mr-7700-multinuclear-application-clinical-trial-100621239","NCT07368036","MR 7700 Multinuclear Application Clinical Trial","MR 7700 Multinuclear Application Clinical Study","Inclusion Criteria:\n\n* • 18 ≤ Age ≤ 75 years old;\n\n  * Clear mind, able to cooperate, and capable of autonomous behavior;\n  * Voluntarily agree to participate in this clinical trial and sign the informed consent form for the subjects\n\nExclusion Criteria:\n\n* • Individuals with claustrophobia.\n\n  * On the day of scanning, the subject's body temperature was above 39.5 ℃.\n  * Plan to become pregnant, pregnant, and breastfeeding women within 6 months.\n  * Other implants, prostheses, foreign bodies, patches, etc. that are not suitable for magnetic resonance imaging examination; There are electronic implants such as pacemakers, stimulators, insulin pumps, cochlear implants, etc.\n  * Critical patients equipped with various rescue devices, as well as subjects with any emergency medical conditions requiring first aid.\n  * Subjects with poor compliance, which the researchers believe should be excluded.\n  * Other situations that the investigators believe are not suitable for participating in this experiment.","75 Years",{"count":153,"type":21},[50],"The purpose of this clinical trial is to use the medical magnetic resonance imaging system MR 7700 to perform phosphorus (31P) and sodium (23Na) scanning imaging on the human body, evaluate the image quality of phosphorus (31P) and sodium (23Na) scanning, as well as the machine convenience, machine stability, and system safety of the entire system.",[343,344,345,346,347],"MR Multinuclear","Image Quality","Device Convenience","Device Stability","System Safety",[349,350],"multinuclear","MR","2026-01-20",{"date":353,"type":30},"2026-01-26",{"date":355,"type":21},"2026-03-01",{"date":357,"type":21},"2026-10-31",{"name":36,"class":37},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":48,"phases":365,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100621240","mr-7700-multinuclear-application-clinical-study-100621240","NCT07368049","Inclusion Criteria:\n\n* 1\\. HCC patient group\n\n  * Age ≥ 18 years;\n  * With clear consciousness, ability to cooperate, and autonomous behavior;\n  * Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;\n  * Patients diagnosed with primary hepatocellular carcinoma by imaging or clinical diagnosis, and who have not received tumor treatment.\n* 2\\. Healthy control group\n\n  * Age ≥ 18 years;\n  * With clear consciousness, ability to cooperate, and autonomous behavior;\n  * Voluntary agreement to participate in this clinical trial and signing of the subject's informed consent form;\n  * No previous history of liver disease.\n\nExclusion Criteria:\n\n* HCC patient group and healthy control group\n\n  * Patients with claustrophobia.\n  * Subject's body temperature \\> 39.5°C on the day of scanning.\n  * Females who plan to be pregnant within 6 months, and pregnant and lactating females.\n  * Patients with other implants, prostheses, foreign bodies, patches, etc. that are not suitable for MRI examination; patients with electronic implants, such as pacemakers, stimulators, insulin pumps, cochlear implants, etc.\n  * Critically ill subjects with various resuscitation devices or those with any emergency medical condition requiring first aid.\n  * Subjects with poor compliance are considered to be excluded by the investigators.\n  * Subjects who are not considered suitable for this trial by the investigators.",{"count":95,"type":21},[50],"The purpose of this clinical study is to perform phosphorus nucleus (31P) and sodium nucleus (23Na) imaging of the liver in patients with primary hepatocellular carcinoma (HCC) and healthy volunteers using the MR 7700 Magnetic Resonance Equipment, in order to explore the manifestations of multinuclear imaging in HCC patients and healthy volunteers.",[368,369],"Hepatocellular Carcinoma","MRI",[371,349,350,372],"HCC","Liver",{"date":353,"type":30},{"date":375,"type":21},"2026-01-05",{"date":377,"type":21},"2026-08-31",{"name":36,"class":37},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":4},"100617346","precise-image-for-interventional-ct-100617346","NCT07317427","Precise Image for Interventional CT","Clinical Study for Precise Image for Interventional CT for Incisive CT and CT 5300 Systems","Inclusion Criteria:\n\n* Subjects scanned by FDA-cleared and marketed Philips Incisive CT or CT 5300 systems, and according to the department standard of care clinical protocols for the applicable clinical scans.\n* Subject age: \\>18 years old.\n* Presence of procedural instrument(s) (e.g., needle, probe, screw) in the CT images.\n\nExclusion Criteria:\n\n* Subject age: 18 years old and below.\n* Absence of procedural instrument(s) (e.g., needle, probe, screw) in the CT images.\n* Scans that were acquired using a kilovoltage peak of 70 kVp (as Precise Image does not support a kilovoltage peak lower than 80 kVp).\n* Scans that the site interventional radiologists have deemed non-suitable for procedural guidance.",{"count":387,"type":21},55,"The purpose of this clinical study is to assess the performance of the Precise Image reconstruction algorithm on interventional CT images acquired from adult patients (\\>18 years old). The analysis will focus on the performance of Precise Image for scans in which procedural instruments (e.g., needle, probe, screw) are present. Clinical data generated from this study is intended to support a proposed expansion of the Indications for Use of Precise Image.\n\nThe study has two objectives:\n\n1. To evaluate the image quality for procedural guidance and procedural confidence of Precise Image compared to the standard-of-care reference (iDose4) for:\n\n   * Interventional CT images of adult patients (\\>18 years old).\n2. To demonstrate non-inferiority of Precise Image to iDose4 for the relevant interventional CT images.",[390],"Computed Tomography","2025-12-18",{"date":375,"type":30},{"date":394,"type":21},"2026-01-31",{"date":396,"type":21},"2026-10-01",{"name":36,"class":37},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":405,"maxAge":17,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100617349","precise-image-for-pediatrics-100617349","NCT07317466","Precise Image for Pediatrics","Clinical Study for Precise Image for Pediatrics for Incisive CT and CT 5300 Systems","Inclusion Criteria:\n\n* Subjects scanned by FDA-cleared and marketed Philips Incisive CT or CT 5300 systems, and according to the department standard of care clinical protocols for the applicable anatomies.\n* Subject age: From 18 months up to and including 18 years of age.\n\nExclusion Criteria:\n\n* Subject age: Below 18 months and above 18 years of age.\n* Scans that were acquired using generic 'Head' and 'Body' scan types (as Precise Image does not support generic 'Head' and 'Body' scan types).\n* Scans that were acquired using a kilovoltage peak of 70 kVp (as Precise Image does not support a kilovoltage peak lower than 80 kVp).\n* Scans that the site radiologists have deemed as non-diagnostic image quality in standard practice (e.g. patient movement).\n* Scans that are not completed due to technical difficulties.","18 Months",{"count":407,"type":21},168,"The purpose of this clinical study is to evaluate the performance of the Precise Image reconstruction algorithm in pediatric patients (specifically, head and body CT imaging of patients from 18 months up to and including 18 years of age). Clinical data generated from this study is intended to support a proposed expansion of the intended population of Precise Image.\n\nThe study has two objectives:\n\n1. To evaluate the image quality and diagnostic confidence of Precise Image compared to the standard-of-care reference (iDose4) for:\n\n   * Head and body CT images of pediatric patients (from 18 months up to and including 18 years of age).\n2. To demonstrate non-inferiority of Precise Image to iDose4 for the relevant anatomy and resolution groups.",[390],[411,412,413],"Precise Image","CT5300","Incisive CT",{"date":375,"type":30},{"date":394,"type":21},{"date":417,"type":21},"2026-09-01",{"name":36,"class":37},{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":433,"locationsCount":4},"100617348","precise-image-for-musculoskeletal-ct-100617348","NCT07317453","Precise Image for Musculoskeletal CT","Clinical Study for Precise Image for Musculoskeletal CT for Incisive CT and CT 5300 Systems","Inclusion Criteria:\n\n* Subjects scanned by FDA-cleared and marketed Philips Incisive CT or CT 5300 systems, and according to the department standard of care clinical protocols for the applicable anatomies.\n* Subject age: Above 18 years old.\n\nExclusion Criteria:\n\n* Subject age: 18 years old and below.\n* Scans that were acquired using generic 'Body' scan type (as Precise Image does not support generic 'Body' scan types).\n* Scans that were acquired using a kilovoltage peak of 70 kVp (as Precise Image does not support a kilovoltage peak lower than 80 kVp).\n* Scans that the site radiologists have deemed as non-diagnostic image quality in standard practice (e.g. patient movement).\n* Scans that are not completed due to technical difficulties.",{"count":427,"type":21},84,"The purpose of this clinical study is to evaluate the performance of the Precise Image reconstruction algorithm for musculoskeletal CT imaging (shoulder, hip, knee) of adult patients (\\>18 years old). Clinical data generated from this study is intended to support a proposed expansion of the Indications for Use of Precise Image.\n\nThe study has two objectives:\n\n1. To evaluate the image quality and diagnostic confidence of Precise Image compared to the standard-of-care reference (iDose4) for:\n\n   * Musculoskeletal CT images (shoulder, hip, knee) of adult patients (\\>18 years old).\n2. To demonstrate non-inferiority of Precise Image to iDose4 for the relevant resolution groups.",[390],{"date":375,"type":30},{"date":394,"type":21},{"date":396,"type":21},{"name":36,"class":37},{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":448,"locationsCount":4},"100617350","clinical-study-for-p-mar-100617350","NCT07317479","Clinical Study for P-MAR","Clinical Study for P-MAR Metal Artifact Reduction Algorithm for Incisive CT and CT 5300 Systems","Precise MAR","Inclusion Criteria:\n\n* Subjects scanned by FDA-cleared and marketed Philips Incisive CT or CT 5300 systems, and according to the department standard of care clinical protocols.\n* Subject age: Above 18 years old.\n* Scans with metal present (orthopedic implants\u002Fjoint prothesis, dental filling\u002Fimplants, spine screw(s), pacemaker, coils, radiotherapy beads, surgical clips\u002Fstaples, metal objects either outside the body or near air, etc.)\n\nExclusion Criteria:\n\n* Subject age: 18 years old and below.\n* CT scans with no metal present.\n* CT scans with metal with motion artifacts.\n* Surview or Locator\u002FTracker.\n* CT scans performed utilizing respiratory gating (e.g., \"pulmo gating\").\n* CT scans performed utilizing cardiac gating.\n* CT Perfusion scans.\n* CCT scans.\n* Scans that the site radiologists have deemed as non-diagnostic image quality in standard practice (e.g. patient movement).\n* Scans that are not completed due to technical difficulties.",{"count":136,"type":21},"The purpose of this clinical study is to evaluate the performance of the P-MAR metal artifact reduction algorithm for CT imaging (with metal present) of adult patients (\\>18 years old).\n\nThe study has two objectives:\n\n1. To evaluate the extent of metal artifacts and diagnostic confidence, and overall image quality (independent of metal artifacts) of P-MAR compared to images without metal correction, and compared to O-MAR, for CT images (with metal present) of adult patients (\\>18 years old).\n2. To demonstrate non-inferiority of P-MAR compared to images without metal correction for the relevant metal groups.",[390],{"date":375,"type":30},{"date":394,"type":21},{"date":396,"type":21},{"name":36,"class":37},{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":466,"locationsCount":4},"100613510","precise-3d-surview-100613510","NCT07267533","Precise 3D Surview","Precise 3D Surview Clinical Study","3D Surview","Inclusion Criteria:\n\n* Subjects scanned by CT 5300 (K232491) and Incisive CT (K212441) according to the department standard of care clinical protocols.\n* Subjects age is over eighteen (18) years1.\n* Patients scanned in supine orientation.\n* Non-contrast CT scan\n* CT scan with standard resolution\n\nExclusion Criteria:\n\n* Subjects age is under or equal 18 years old\n* Patients are not scanned in supine orientation.\n* Contrast-enhanced CT scans.\n* CT scans with high resolution\n* Scans that are not completed due to technical difficulties",{"count":458,"type":21},274,"The purpose of the study is to assess the performance of Precise 3D Surview on CT 5300 and Incisive CT Scanners as compared with manual annotation by experienced CT technologists.\n\n* To evaluate the acceptance rate of the Auto 3D Planning Box compared with manual annotation by experienced CT technologists.\n* To evaluate the acceptance rate of the Auto Suggestion for Locator compared with manual annotation by experienced CT technologists.\n* To evaluate the acceptance rate of the Auto Planning for Truncated Anatomies (lung and liver) compared with manual annotation by experienced CT technologists.\n* To evaluate the acceptance rate of Auto Planning and Symmetry Correction for Tilted Head compared with manual annotation by experienced CT technologists.",[390],"2025-12-04",{"date":463,"type":30},"2025-12-05",{"date":394,"type":21},{"date":396,"type":21},{"name":36,"class":37},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":184},"100544685","project-mountain---comparing-spo2-and-sao2-for-accuracy-100544685","NCT06372106","Project Mountain - Comparing SpO2 and SaO2 for Accuracy","Philips FAST picoSAT Convenience Sampling for Clinical Performance in Neonate, Infant, and Pediatric Patients","Inclusion Criteria:\n\n* Subject aged 18 years or older or parent\u002Flegal guardian of subject aged less than 18 years, willing and able to understand and provide written informed consent\u002Fassent.\n* Weight and\u002For age within intended use of at least one SpO2 sensor under test at time of enrollment.\n* Willing and able to wear study devices in addition to SoC devices and during SoC procedures.\n* In-patient within a neonatal or pediatric intensive care unit (e.g. NICU, PICU, PCICU).\n* Has arterial access and ability to have arterial blood samples drawn as part of their SoC and analyzed by CO-Oximetry.\n\nExclusion Criteria:\n\n* Known pregnancy or lactating females (self-reported)\n* Injury, wounds, physical malformation, hyperkeratosis, or compromised\u002Fnon-intact skin at sensor application site (i.e. fingers, toes, hands, feet, ears, nasal ala). Note: Certain malformations may be allowed if determined it would not affect application of sensor with the pulse oximetry system.\n* Self-reported severe contact allergies to standard adhesives or other materials found in pulse oximetry sensors. Note: Subject may be considered eligible if subject can wear non-adhesive sensor.\n* Unwillingness or inability to remove nail polish or artificial nails from sensor application site.\n* Nail fungus on sensor application site.\n* Wearing and unable to remove jewelry from sensor application site.\n* Dye injection within 48 hours of enrollment.\n* Known dysfunctional hemoglobin levels (COHb \\>3%, MetHb \\>2%, and ctHb \\\u003C10g\u002Fdl)\n* Undergoing phototherapy for neonatal hyperbilirubinemia during arterial blood sampling",{"count":475,"type":21},560,"The main goal of this study is to look at the performance of the neonatal, infant, and pediatric Philips SpO2 sensors with the Philips FAST Pulse Oximetry technology. Oxygen saturation measurements (SpO2) will be obtained via pulse oximetry and invasive arterial oxygen measurements (SaO2) will be obtained via arterial blood samples as part of your clinical care and assessed by co-oximetry. The study will aim to enroll a diverse population to help us understand the impact of skin pigmentation.",[478,479,480,481],"SpO2","Nasal Alar Collapse, Bilateral","Oxygen","Measurement","2025-04-01",{"date":484,"type":30},"2025-04-02",{"date":486,"type":30},"2024-04-04",{"date":488,"type":21},"2025-12",{"name":36,"class":37},{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":496,"targetDuration":96,"studyType":22,"phases":4,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":511,"locationsCount":38},"100427037","heartstart-hs1-defibrillator-event-registry-100427037","NCT04840797","HeartStart HS1 Defibrillator* Event Registry","Inclusion Criteria:\n\n* Have been suspected of a circulatory arrest for any cause.\n* Have had HeartStart HS1 Defibrillator with electrodes:\n\nAdult SMART Pads Cartridge \\[REF: M5071A\\], Infant\u002FChild SMART Pads Cartridge (REF:M5072A) applied to their body and powered up with HS1 battery (Model M5070A), regardless of whether a defibrillation shock was delivered\n\nExclusion Criteria:\n\n* Subjects will be excluded if any of the following are present:\n* AED or pad use other than the HeartStart HS1 Defibrillator with above referenced Philips electrode pads. Note: Use of a device other than the Philips HeartStart HS1 AED does not preclude enrollment if the AED or an Advanced Life Support defibrillator was used after the HeartStart HS1 AED.\n* AED used for training purposes.",{"count":497,"type":21},1400,"A Prospective study on the performance and safety of the HeartStart OnSite (Model M5066A) \\& HeartStart Home (Model M5068A) Defibrillator device data.",[500],"Sudden Cardiac Arrest",[502,503,504],"AED","Post -Market","Cardiology","2025-02-25",{"date":507,"type":30},"2025-02-26",{"date":509,"type":30},"2021-02-25",{"date":84,"type":21},{"name":36,"class":37},{"id":513,"slug":514,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":518,"targetDuration":96,"studyType":22,"phases":4,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":38},"100381764","heartstart-frx-defibrillator-event-registry-100381764","NCT04250857","HeartStart FRx Defibrillator Event Registry","Inclusion Criteria:\n\n* Subjects accepted into the study must: have been suspected of a circulatory arrest for any cause\n* Have had HeartStart FRx AED with electrodes: HeartStart SMART PADS II applied to their body and powered up, regardless of whether a defibrillation shock was delivered\n\nExclusion Criteria:\n\n* AED or pad use other than the HeartStart FRx AED with electrodes : HeartStart SMART PADS II\n* AED used for training purposes.",{"count":497,"type":21},"This post market clinical follow-up study is a multi-center, non-randomized, unblinded, observational registry of the performance of the FRx Automated external defibrillator (AED) used in conjunction with electrodes with or without use of the infant\u002Fchild key. The registry is focused only on on post-event data collection and does not prescribe any device usage. This registry has several safeguards in place to prevent against selections bias, including enrollment of all participants who have pads placed. This registry will evaluate the safety and verify the clinical performance of the device in relation to its claims, when used in accordance with the Device Manual.",[500],{"date":507,"type":30},{"date":523,"type":30},"2019-11-04",{"date":84,"type":21},{"name":36,"class":37},""]